These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 29989000)
21. Long-term Outcome of Adult Onset Idiopathic Minimal Change Disease. Colattur SN; Korbet SM Saudi J Kidney Dis Transpl; 2000; 11(3):334-44. PubMed ID: 18209325 [TBL] [Abstract][Full Text] [Related]
22. Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia. Zhuang J; Zhao Z; Zhang C; Song X; Lu C; Tian X; Jiang H Front Med (Lausanne); 2022; 9():1059740. PubMed ID: 36405580 [TBL] [Abstract][Full Text] [Related]
23. Ultra-low-dose rituximab is effective for the treatment of patients with minimal change disease - A retrospective study. Wang C; Zhang MZ; Li LX; Yun XY; Chen CM; Wang FF; Li B J Formos Med Assoc; 2024 Jun; ():. PubMed ID: 38906733 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of Rituximab and Its Biosimilar in Treating Adult Steroid-Dependent Minimal Change Disease and Relapse. Shan HY Cureus; 2023 Nov; 15(11):e49200. PubMed ID: 38130516 [TBL] [Abstract][Full Text] [Related]
25. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467 [TBL] [Abstract][Full Text] [Related]
26. A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab. Nishikawa M; Shimada N; Kurahashi M; Watanabe K; Kanzaki M; Fukuoka K; Asano K CEN Case Rep; 2024 May; ():. PubMed ID: 38775892 [TBL] [Abstract][Full Text] [Related]
27. Rituximab for troublesome cases of childhood nephrotic syndrome. Safdar OY; Aboualhameael A; Kari JA World J Clin Pediatr; 2014 Nov; 3(4):69-75. PubMed ID: 25512892 [TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease. Lionaki S; Mantios E; Tsoumbou I; Marinaki S; Makris G; Liapis G; Vergandis C; Boletis I J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441929 [TBL] [Abstract][Full Text] [Related]
30. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Huang JJ; Hsu SC; Chen FF; Sung JM; Tseng CC; Wang MC Am J Nephrol; 2001; 21(1):28-34. PubMed ID: 11275629 [TBL] [Abstract][Full Text] [Related]
31. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related]
32. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536 [TBL] [Abstract][Full Text] [Related]
33. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657 [TBL] [Abstract][Full Text] [Related]
34. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432 [TBL] [Abstract][Full Text] [Related]
35. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Counsilman CE; Jol-van der Zijde CM; Stevens J; Cransberg K; Bredius RG; Sukhai RN Pediatr Nephrol; 2015 Aug; 30(8):1367-70. PubMed ID: 26054711 [TBL] [Abstract][Full Text] [Related]
37. Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab-A Case Report. Zagorec N; Klarić D; Klarić M; Horvatić I; Šenjug P; Horaček M; Nikić J; Galešić Ljubanović D; Galešić K J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143201 [TBL] [Abstract][Full Text] [Related]
38. Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists. Koizumi M; Ishimoto T; Shimizu S; Sasaki S; Kurita N; Wada T PLoS One; 2024; 19(3):e0299053. PubMed ID: 38551948 [TBL] [Abstract][Full Text] [Related]
39. Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults. Wieland I; Kentouche K; Jentzsch M; Lothschütz D; Graf N; Sykora KW Pediatr Blood Cancer; 2015 May; 62(5):823-9. PubMed ID: 25623397 [TBL] [Abstract][Full Text] [Related]
40. Rituximab therapy in adults with steroid-dependent nephrotic syndrome. Zhong H; Li HY; Zhou T; Weng W Arch Med Sci; 2023; 19(3):577-585. PubMed ID: 37313189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]